An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00833911
Recruitment Status : Completed
First Posted : February 2, 2009
Results First Posted : June 2, 2009
Last Update Posted : April 30, 2012
Information provided by (Responsible Party):
Labopharm Inc.

January 29, 2009
February 2, 2009
April 8, 2009
June 2, 2009
April 30, 2012
April 2003
July 2004   (Final data collection date for primary outcome measure)
Number of Patients Having Experienced an Adverse Event During the 6-12 Month Open-Label Safety Participation [ Time Frame: 6 months and 12 months ]
Spontaneous reports of adverse events were recorded for the entire study population, the 6-months safety population and the 12-months safety population
  • Adverse Events
  • Physical Exams
  • Vital Signs
  • Clinical Laboratory Examinations (Hematology, Biochemistry, Urinalysis)
  • Drop out rate
  • Patient and Physician Global Ratings
Complete list of historical versions of study NCT00833911 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee
An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee
The purpose of this study is to collect information regarding the long-term (6 and 12 months) safety of Tramadol HCl Once-A-Day(OAD) 300 mg.
Not Provided
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Osteoarthritis, Knee
Drug: Tramadol Once A Day
Experimental: Tramadol Contramid® OAD
Intervention: Drug: Tramadol Once A Day
Mongin G. Tramadol extended-release formulations in the management of pain due to osteoarthritis. Expert Rev Neurother. 2007 Dec;7(12):1775-84. Review.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
July 2004
July 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or Female patients between the ages of 40-75 with a diagnosis of Osteoarthritis of the knee consistent with the American College of Rheumatology (ACR) Clinical Classification Criteria for Arthritis of the Knee (Altman, R. et al., 1991):

    • Current knee pain,
    • Less than 30 minutes of morning stiffness with or without crepitus on active motion,
    • Confirmation either by arthroscopy or radiologist's report (X-rays showing osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation}) within two years prior to entry into the study.
  2. Erythrocyte Sedimentation Rate (ESR) < 40 mm/hour.
  3. Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale total score of >= 150 mm at baseline. (5 questions/100 mm scale each with an averaged response of 30 mm or higher per question).
  4. Oral and written language comprehension at a level sufficient to comply with the protocol and complete study-related materials.
  5. The Patient has signed and dated the Research Ethics Board (REB) approved, written, informed consent prior to study participation.

Exclusion Criteria:

  1. Known rheumatoid arthritis or any other rheumatoid disease.
  2. Secondary arthritis i.e. any of the following: septic arthritis; inflammatory joint disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia; Wilson's disease; Ochronosis; Haemochromatosis; Osteochondromatosis; heritable arthritic disorders; or collagen gene mutations.
  3. Obesity Class II (Body Mass Index (BMI) >= 35) (National Institutes of Health (NIH), 2000).
  4. Major illness requiring hospitalization during the 3 months before commencement of the screening period.
  5. Patients who are unwilling to stop taking pain medication other than the study medication (for arthritis or other types of pain) or are unwilling to stop taking other medications for the treatment of osteoarthritis (OA).
  6. Patients who have previously failed tramadol hydrochloride (HCl) therapy or those who discontinued tramadol HCl due to adverse events.
  7. Patients who are taking or within the last 3 weeks have taken the following medications: monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors; or other drugs which reduce seizure threshold.
  8. Patients who are taking or have taken another investigational agent within the last 30 days.
  9. Patients with a history of seizure disorder other than Infantile Febrile Seizures.
  10. Patients who are opioid dependent.
  11. Patients with bowel disease causing malabsorption.
  12. Patients who are pregnant or lactating or patients of child-bearing potential who are unwilling to utilize a medically approved method of contraception during participation in this clinical trial.
  13. Patients with significant liver disease, defined as active hepatitis or elevated liver enzymes >3 times the upper boundary of the normal range.
  14. Patients with significant renal disease, defined as creatinine clearance <30 mL/min as estimated by the method of Levey et al., 1999.
  15. Current substance abuse or dependence, other than nicotine.
  16. Allergy or adverse reaction to tramadol or any structurally similar drugs e.g. opiates.
  17. Any other condition that, in the opinion of the investigators, would adversely affect the patient's ability to complete the study or its measures.
Sexes Eligible for Study: All
40 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Labopharm Inc.
Labopharm Inc.
Not Provided
Not Provided
Labopharm Inc.
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP